Lv5
1328 积分 2024-07-16 加入
Advantages and limitations of the inclusion of ascorbic acid on nitrosamine mitigation in pharmaceutical drug products
1个月前
已完结
A comprehensive discussion on analytical method development and validation of a USP type-IV dissolution method for dexamethasone in a combination ophthalmic suspension with povidone-iodine
1个月前
已关闭
Do we worry too much about polysorbate degradation? An industry-wide perspective with real-life case studies
1个月前
已完结
Recrystallization can stop nitrosamine formation in ranitidine hydrochloride
1个月前
已完结
Change management considerations for orally inhaled and nasal drug products and other drug device combination products in the European Union
1个月前
已关闭
Stability characterization for pharmaceutical liposome product development with focus on regulatory considerations: An update
1个月前
已完结
Development of a size exclusion chromatography cartridge-based analytical method for determination of free drug in nano-liposomal oncology drug formulations
1个月前
已完结
Challenges of nanoparticle albumin bound (nab™) technology: Comparative study of Abraxane® with a newly developed albumin-stabilized itraconazole nanosuspension
2个月前
已完结
Micro-flow imaging multi-instrument evaluation for sub-visible particle detection
2个月前
已完结
Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): part I. Albumin-bound betulinic acid nanoparticles (ABBns)
2个月前
已完结
皖公网安备34019202002308
